Trial Profile
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Apr 2023
Price :
$35
*
At a glance
- Drugs Avelumab (Primary)
- Indications Carcinoma; Malignant thymoma
- Focus Adverse reactions; Therapeutic Use
- 08 Nov 2022 Planned primary completion date changed from 30 Sep 2024 to 30 Jun 2024.
- 13 Oct 2022 Planned End Date changed from 30 Sep 2023 to 30 Jun 2025.
- 13 Oct 2022 Planned primary completion date changed from 30 Sep 2023 to 30 Sep 2024.